Selective serotonin reuptake inhibitors includ- Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Escitalopram Refer- Fluoxetine 

Avoid concurrent administration with antiarrhythmics, antipsychotics, cyclosporin, imidazole and triazole antifungals,tricyclic antidepressants Concurrentuse with CYP3A4 inhibitors may increase plasmalevels of reboxetine. Concurrent use with ergot alkaloids may increase BP. Risk of hyperetensive crisis, when used with MAOIs

Depressive illness

Insominia, dizziness, increase sweating, impotence Dry mouth, constipation, urinary hesistency, postural hypotension, dysuria, parethesia, hyponatremia tachycardia

Special pecautions-

Renal and hepatic impairment, benign prostatic hyperplasia cardiac disorders, epilepsy bipolar disorders urinary retension, glaucoma may impair ability to perform tasks, driving or operating machinery, Monitor for signs of clinical worsening eg. suicidal tendency esp during th initial phase of treatment

Indications:

Depressive illness

Dosage

Typical 8-10mg daily

Selective serotonin reuptake inhibitors includ- Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Escitalopram Refer- Fluoxetine

Pharmacology:

Roboxtetine selectively and potentially inhibits norephinephrine reuptake.It has been shown to have negligable affinity for serotonin and dopamine uptake sites for adrenergic and histaminergic receptors, and only weak affinity for muscarinic receptors.

Pharmacokinetics:

It is rapidly absorbed after oral administration. The tmax is about 2hrs and terminal half-life of elimination is 13 hrs, allowing a twice daily administration. Elimination is principally by renal route.

Use with caution during pregnancy and lactation.